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Chronic administration of anticonvulsants but not
antidepressants impairs bone strength: clinical implications
PW Gold1, MG Pavlatou1, D Michelson2, CM Mouro3, MA Kling4,5, M-L Wong6, J Licinio6 and SA Goldstein3
Major depression and bipolar disorder are associated with decreased bone mineral density (BMD). Antidepressants such as
imipramine (IMIP) and speciﬁc serotonin reuptake inhibitors (SSRIs) have been implicated in reduced BMD and/or fracture in older
depressed patients. Moreover, anticonvulsants such as valproate (VAL) and carbamazepine (CBZ) are also known to increase
fracture rates. Although BMD is a predictor of susceptibility to fracture, bone strength is a more sensitive predictor. We measured
mechanical and geometrical properties of bone in 68 male Sprague Dawley rats on IMIP, ﬂuoxetine (FLX), VAL, CBZ, CBZ vehicle and
saline (SAL), given intraperitoneally daily for 8 weeks. Distinct regions were tested to failure by four-point bending, whereas load
displacement was used to determine stiffness. The left femurs were scanned in a MicroCT system to calculate mid-diaphyseal
moments of inertia. None of these parameters were affected by antidepressants. However, VAL resulted in a signiﬁcant decrease in
stiffness and a reduction in yield, and CBZ induced a decrease in stiffness. Only CBZ induced alterations in mechanical properties
that were accompanied by signiﬁcant geometrical changes. These data reveal that chronic antidepressant treatment does not
reduce bone strength, in contrast to chronic anticonvulsant treatment. Thus, decreased BMD and increased fracture rates in older
patients on antidepressants are more likely to represent factors intrinsic to depression that weaken bone rather than
antidepressants per se. Patients with affective illness on anticonvulsants may be at particularly high risk for fracture, especially as
they grow older, as bone strength falls progressively with age.
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INTRODUCTION
Recent data in large populations of older individuals indicate that
speciﬁc serotonin reuptake inhibitors (SSRIs) are associated with
the risk of decreased bone mineral density (BMD) and/or hip
fracture.1–3 Other studies report that both SSRIs and tricyclic
antidepressants (TCAs) increase the risk of hip fracture in older
patients without commenting on BMD.4–6 The impact of
antidepressants on BMD is complicated by the fact that many
papers also ﬁnd that major depression is associated with loss of
BMD per se.7–9 This loss of BMD in patients with major depression
potentially reﬂects a number of hormonal alterations that may be
risk factors for decreased BMD, including hypercortisolism,
decreased secretion of growth hormone and hypothalamic
hypogonadism.10–12 In addition, melancholic patients with major
depression have around-the-clock increases in plasma and CSF
norepinephrine secretion,13 and recent data indicate that
sympathetic drive contributes to bone loss.14 Depressed patients
are also in a mild proinﬂammatory state, characterized by changes
such as increased plasma IL-615 and acute phase protein levels.16 It
is well known that inﬂammation has a major role in some forms of
osteoporotic bone loss,17 especially at the hip. In our premeno-
pausal women with major depression, bone loss was considerably
greater at the hip than at the spine,7 in contrast to the usual
pattern of greater loss of vertebral bone in common forms of
osteoporosis. This pattern is more compatible with inﬂammatory
causes of osteoporosis. Thus, inﬂammation may be particularly
important in the bone loss of depressive illness.
Anticonvulsants are also well known to contribute to reductions
in BMD and increase the rate of bone fracture. These compounds
are used not only to treat epilepsy, but also major depressive
illness as well. Several factors may contribute to the increased
fracture risk reported in patients with epilepsy. Epileptic seizures
may per se lead to injury. In addition, subjects with epilepsy,
especially if children, may have insufﬁcient dietary intake of
vitamin D, limited sun exposure, and decreased ambulation and
physical activity, all nonspeciﬁc factors that can lead to impaired
bone structure and function.18 However, anticonvulsants may also
affect bone mass by speciﬁc mechanisms. Their mechanisms
include impaired calcium absorption, induction of microsomal
enzymes with consequent accelerated hepatic catabolism of
vitamin D, secondary hypoparathyroidism, and
osteomalacia.19–21
There is extensive and long-term clinical use of antidepressant
and antiepileptic agents, and drug-induced osteoporosis is a
preventable condition. We thus decided to test whether chronic
administration of antidepressants and anticonvulsants to rats may
affect mechanical strength, an extremely important determinant
of fracture risk in low impact trauma. We know several
mechanisms by which anticonvulsants can contribute to low
BMD or bone fracture, but knowing more about their impact on
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speciﬁc parameters of bone strength may help contribute to
methods of reducing the risk to bone health posed by
anticonvulsants.
None of the factors promoting bone loss attributable to
anticonvulsants have yet been found as a consequence of
antidepressant treatment. Showing whether or not antidepres-
sants decrease bone strength could help clarify the extent to
which low BMD or fracture in depression can be, in part,
attributable to medication, or is an intrinsic component of
depressive illness. Bone strength may be more important than
BMD in conferring susceptibility to bone fracture, so that BMD and
bone strength are not necessarily synonymous. Therefore, it is of
substantial clinical importance to establish whether and how




Sixty-eight male Sprague Dawley rats were treated either with the
antidepressants imipramine (IMIP) or ﬂuoxetine (FLX); with the
anticonvulsants valproate (VAL) or carbamazepine (CBZ); or given
a sham treatment via daily intraperitoneal injections for 8 weeks. A
saline (SAL) sham treatment was used as the control for the IMIP,
FLX and VAL groups, while carbamazepine vehicle (CBZ-V) was
used as the control for the CBZ group. The FLX group was
administered 1mg kg− 1 body weight of ﬂuoxetine; the IMIP group
was given 5mg kg− 1 of IMIP; the VAL group received 250 -
mg kg− 1 of valproate, all in 0.5 ml saline vehicle. The SAL group
was given 0.5 ml saline alone. The CBZ group was treated with
40mg kg− 1 body weight of CBZ in a 1-ml propylene glycol/
alcohol/saline vehicle. The CBZ-V group received a sham
treatment of 1 ml of CBZ-V alone.
Mechanical testing
The right femurs from 53 rats, which had been stored fresh-frozen,
were tested to failure in four-point bending using an MTS
servohydraulic testing machine (Minneapolis, MN, USA) at a
constant displacement of rate of 5 mm s− 1 (see Figure 1). Load-
displacement data were acquired and used to determine loads
and displacements to both yield and failure. Stiffness was
calculated as the slope of the linear portion of the load-
displacement curve.
Geometrical analysis
The left femurs from 68 rats were scanned in a MicroCT system,
and three-dimensional digital images were reconstructed at a
resolution of 50 μm. The images were thresholded to distinguish
bone from non-bone voxels, and the analysis region was deﬁned
as the mid-50% region of the bone (mid-diaphysis). Cross-
sectional area, cortical thickness and moments of inertia were
determined for each slice, and then averaged along the length of
the analysis region. Moment of inertia is a mathematical
representation of the distribution of bone material away from
the neutral bending axis of the bone, and is directly related to
mechanical properties in bending (Please see Appendix 1 for a
further explication of this term).
Statistical analysis
A one-way analysis of variance was used to compare the FLX, IMIP
and VAL groups with the SAL group, and to compare the CBZ and
CBZ-V groups. Tukey’s post hoc test was used for comparisons
between groups with Po0.05 considered statistically signiﬁcant.
RESULTS
Three months of daily treatment with IMIP and FLX had no impact
on stiffness, bone yield or geometric properties of bone consisting
of moment of inertia, cortical thickness and cross-sectional area
(Figure 2).
In general, anticonvulsant drug therapy causes a decrease in
mechanical properties of whole bones. Both the VAL and CBZ
groups exhibited signiﬁcant decreases in stiffness and yield load
(see Figures 2 and 3). The VAL group exhibited an 18.5% reduction
in stiffness and a 25.3% reduction in yield load when compared
with the SAL group. Treatment with CBZ resulted in a 21.3%
decrease in stiffness and 26.5% decrease in yield load when
compared with the CBZ-V group. Similar trends were seen in
failure load results, although the comparison was only statistically
signiﬁcant between the CBZ and CBZ-V groups.
Figure 1. The femurs were loaded to failure by a custom designed
four-point bending ﬁxture secured within the structure of an MTS
materials testing system. The region of the mid-diaphysis subjected
to load between the four loading points corresponded precisely to
the volume of bone evaluated by MicroCT.
+ p=0.055 vs. SA 
* p<0.05 vs. CC
Figure 2. Anticonvulsant drug therapy demonstrated a signiﬁcant
decrease in whole bone stiffness. +P= 0.055 vs SA. *Po0.05 vs CC.
CA, carbamazepine; CC, controls; FL, ﬂuoxetine; IM, imipramine; SA,
saline; VA, valproate.
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These alterations in mechanical properties were accompanied
by signiﬁcant geometrical changes only in the CBZ group (see
Table 1). Cross-sectional area, moment of inertia and cortical
thickness were signiﬁcantly decreased in the CBZ group when
compared with the CBZ-V group. The CBZ group exhibited an
18.3% reduction in moment of inertia when compared with the
CBZ-V group, whereas the VAL group only showed a 7.7%
decrease when compared with the SAL group (see Figure 4).
DISCUSSION
Eight-week-old male Sprague Dawley rats were treated either with
the antidepressants, IMIP or FLX; anticonvulsants, VAL or CBZ; or
given a sham treatment, saline SAL or CBZ vehicle via daily
intraperitoneal injections for 8 weeks. The right femur was tested
to failure in four-point bending. Load-displacement data were
used to determine stiffness, and loads and displacements to both
yield and failure. The left femurs were scanned in a MicroCT
system to calculate cross-sectional area, cortical thickness and
moments of inertia of the mid-diaphyseal region. Neither IMIP nor
FLX had any signiﬁcant effects on cross-sectional area, moment of
inertia and cortical thickness. On the other hand, both anti-
convulsants adversely inﬂuenced multiple determinants of bone
strength.
SSRIs and TCAs: putative effects on BMD and hip fracture
Diem et al.1 studied 2722 older women prospectively over a 5-year
period and concluded that SSRIs led to a signiﬁcant reduction in
BMD at the hip. This ﬁnding could be complicated by the fact that
patients with depressive illness may lose bone faster than
matched controls. Moreover, its functional signiﬁcance is not
clear as loss of BMD does not always correlate precisely with bone
strength of relevance to the liability to fracture (vide infra).
Haney et al.2 studied 5995 men 65 years and older cross-
sectionally, showing that SSRIs were also associated with
signiﬁcant losses of BMD at the hip and spine, while subjects on
TCAs or trazadone had no loss of BMD. Richards et al.3 studied
5008 community dwelling adults age 50 and above prospectively
over a period of ﬁve years and also showed a clinically-relevant
association between SSRI use, BMD loss at the hip, and a trend for
BMD loss at the spine. SSRI treatment was also associated with
twofold increased incidence of fragility fracture greater at the hip
than at the spine.
Three studies have suggested that both SSRIs and TCAs are
associated with increased risk of hip fracture. Liu et al.5 studied a
group of 8239 patients aged 66 years and older and found a
twofold increase in hip fracture for both drugs. Similarly, Ziere
et al.6 studied 1289 elderly subjects and found a greater than
twofold increase in hip fracture for both drugs. None of these
studies examined measures of BMD.
Bone has functional serotonergic system and responds to
norepinephrine as well
In vitro and in vivo data in experimental animals indicate a
functioning serotonin system in bone. Osteoblast and osteoclasts
both express a serotonin transporter system, with mechanisms for
responding to and taking up serotonin.22 Functional receptors
for serotonin and the serotonin transporter have been identiﬁed
in osteoblasts, osteoclasts and osteocytes. Serotonin has been
shown to induce murine osteocytes. Serotonin and human
osteoclast differentiation in vitro. The SSRI FLX inhibits osteoblast
differentiation and osteoclast differentiation,23 effects that would
have opposing effects on BMD.
Serotonin transporter (5HTT) knockout is associated with
decreased bone accrual during growth. The authors suggest that
this might relate to an effect in the 5HTT in reducing skeletal
responsiveness to mechanical loading. However, using the
Figure 3. Similar to the results for stiffness, the anticonvulsants
signiﬁcantly reduced the load to yield in femurs. **Po0.005 vs
control. CA, carbamazepine; CC, controls; FL, ﬂuoxetine; IM,
imipramine; SA, saline; VA, valproate.
Table 1. Geometrical properties of antidepressant- and
anticonvulsant-treated rats
CSA (mm2) CT (mm) Ixx (mm4)
IM (n= 15) 6.27± 0.49 0.696± 0.052 9.54± 1.35
FL (n= 12) 6.48± 0.50 0.725± 0.052 9.75± 1.67
VA (n= 9) 6.36± 0.36 0.740± 0.095 9.32± 0.94
SA (n= 12) 6.55± 0.34 0.715± 0.026 10.10± 0.34
CA (n= 9) 5.53± 0.46** 0.640± 0.044* 7.78± 1.03**
CC (n= 11) 6.23± 0.33 0.671± 0.020 9.52± 1.24
Abbreviations: CA, carbamazepine; CC, controls; CSA, cross-sectional area;
CT, cortical thickness; FL, ﬂuoxetine; IM, imipramine; Ixx, moment of inertia
along x-x axis; SA, saline; VA, valproate. All values expressed as mean± s.d.
*Po0.05 vs CC. **Po0.005 vs CC.
** P<0.005 vs. CC
Figure 4. Only the anticonvulsant CBZ demonstrated a signiﬁcant
reduction in the moment of inertia, reﬂecting a change in the cross-
sectional geometry. **Po0.005 vs CC. CA, carbamazepine; CC,
controls; FL, ﬂuoxetine; IM, imipramine; SA, saline; VA, valproate.
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established loading model, 5HTT− /− and 5HTT+/+ mice were
exposed to identical osteogenic stimuli, no inﬂuence of the null
mutation was found on skeletal growth.
Activation of the sympathetic nervous system promotes bone
resorption.14,24 Yirmiya et al.25 found that sympathetic nervous
system activation in response to behavioral stressors causes bone
loss in association with behavioral features of depression. A
tricyclic mediated increase in bone fracture is not necessarily
compatible with the clinical ﬁndings that TCAs are associated with
an increase in the fracture rat via actions on the noradrenergic
system. Thus, TCAs reduce sympathetic outﬂow signiﬁcantly on
one hand, while serving as norepinephrine reuptake blockers on
the other. Moreover, even if tricyclics did increase availability of NE
at receptors located on bone, their effects are so numerous that
this effect alone might not necessarily lead to pathologic
bone loss.
Despite responsiveness to monoaminergic inputs, loss of BMD and
fractures may not be related to antidepressants
We have previously noted that even young, premenopausal
women with major depression have signiﬁcant losses in BMD
greater at the hip than at the spine. Many other studies ﬁnd
reduced BMD in both male and female populations of patients
with depressive illness (for example, 7–9). The etiology of this loss
of BMD is not known, but, as noted earlier, is likely to represent
many factors, including a proinﬂammatory state, which is
associated with preferential loss of bone at the hip compared
with vertebral loss. The activation of the HPA axis and sympathetic
nervous system, as well as inhibition of the growth hormone and
gonadal axes could also contribute.
The data presented here suggest that antidepressants do not
contribute to bone fractures after minimal trauma in older
patients as these drugs do not reduce bone strength. Thus,
increased fracture in older patients on antidepressants is likely to
reﬂect factors intrinsic to depression itself. Accordingly, more older
depressed patients will be on antidepressants than non-depressed
patients, and hence, the fracture rate will be greater in patients on
antidepressant treatment. Thus, preclinical studies showing that
serotonin systems exist within bone and that bone is responsive
to noradrenergic input do not, in themselves, implicate anti-
depressants in the diathesis to bone fracture in older depressed
patients.
Clinical implications: relationship between bone density, bone
strength and susceptibility to fracture—who should be watched
carefully
The assumption that BMD equates with bone strength and
resistance to fracture has not been fully validated, especially in
younger individuals.26 Rather, resistance to fracture is a composite
of its microarchitecture, accumulated microscopic damage and
the quality of collagen, mineral crystal size and bone turnover.
Many lines of evidence challenge the generally accepted
orthodoxy that bone density is the best way to assess strength
of bone. Indeed, denser bone is not always stronger. This
discrepancy came to light with the use of sodium ﬂuoride to
treat osteoporosis. Although sodium ﬂuoride produced large
increases in density, ﬂuoride made the bone more brittle because
it changed the quality of the mineral and rendered it more
susceptible to fracturing, especially in vertebral fracture regions.
Thus BMD cannot always be considered a straightforward
surrogate marker for bone strength and resistance to fracture,26
though the two are likely to be related.
Young bone and older bone differ in strength, even with similar
bone density. Hence, young bone is stronger than older bone
across all levels of bone mass. Moreover, clinical studies showed
that the drugs approved for treating osteoporotic fractures
generally fare better than we would expect from their effects on
bone density.27 Thus, bones become stronger before they grow
more dense. These data suggest that premenopausal women with
loss of BMD are not necessarily more susceptible to fracture
because of other factors associated with younger age such as high
quality collagen. However, they are losing BMD faster than non-
depressed controls and should be followed closely after meno-
pause, when vulnerability to fracture increases because of loss of
strength and of estrogen.
Like BMD, bone strength decreases progressively as a function
of age. In older individuals, decreased bone strength increases
fracture risk. As BMD loss is greater in premenopausal women at
the hip than at the spine, fractures may be a particular problem for
older women who suffer from depression, a premise validated by
clinical studies. Almost all of the papers cited earlier about
antidepressant use and fractures in older women speciﬁcally
indicated a preferential effect on hip fractures over fractures of the
spine.4,5
Anticonvulsants
Anticonvulsant drugs such as CBZ and VAL are well known to
affect BMD by altering the biochemical and mineral composition
of bone tissue, and have been associated with a higher
predisposition to bone fracture.28 These have been hypothesized
to be caused by a vitamin D deﬁciency similar to osteomalacia.19 A
recent study suggested that decreased BMD in patients treated
with VAL might also be associated with increased bone resorption.
VAL and CBZ may also interact with glucocorticoids in promoting
bone loss.29
In contrast to antidepressants, we report here that anti-
convulsant treatments have a substantial effect on mechanical
and geometrical properties of bone (Table 2). The detrimental
effects of CBZ on mechanical properties of bone are paralleled by
a similar alteration in moment of inertia, indicating that this drug
affects both the geometry of bone and its material properties. In
Table 2. General effects
Antidepressants Anticonvulsants Sham treatment
Imipramine Fluoxetine Valproate (VAL) Carbama (CBZ) Saline (SAL) Carbama Ctrl
Stiffness ↓ 18.5%a ↓ 21%b
Yield ↓ 25.3% ↓ 26%
Moment of inertia ↓ 2.2% ↓ 26.3%
Stiffness
Geometrical changes Yes
aCompared with saline. bCompared with carbamazepine control. Anticonvulsants decreased the mechanical properties of the whole bone. Both valproic acid
(VAL) and carbamazepine (carbama) reduced stiffness (18.5% and 21.3% compared with saline and carbamazepine controls, respectively) and yield (25.3% and
26.4% compared with saline and carbamazepine controls, respectively). Alterations in mechanical properties were accompanied by geometrical changes
(26.3% reduction in the moment of inertia) in the carbamazepine group only. No signiﬁcant changes in the effects of antidepressants.
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contrast, decreases in mechanical properties caused by VAL were
not associated with concomitant changes in cross-sectional
geometry. Therefore, this drug treatment is likely to exert its
effect on bone properties through changes in material properties
of the bone tissue and not geometrical alterations. Previous
clinical studies on the effects of VAL and CBZ on BMD in humans
reported that VAL monotherapy, but not CBZ, signiﬁcantly reduces
axial and appendicular BMD.18 This indicates that material pro-
perty alterations in VAL-treated animals may be related, in part, to
changes in mineralization. These results portray a potentially
important association between anticonvulsant therapy and bone
mass, and may reveal a novel mechanism affecting its regulation.
Anticonvulsants such as VAL and CBZ are often used not only in
patients with epilepsy, but also in patients with bipolar disorder.
Despite the fact that BMD and bone strength do not always
correlate, BMD should be followed in depressed patients on
anticonvulsants, as bone strength is likely to correlate with BMD,
at least partially. The combination of depressive illness, anti-
convulsants and old age may be particularly toxic to bone health.
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APPENDIX
The moment of inertia of an object about a given axis describes
how difﬁcult it is to change its angular motion about that axis.
Therefore, it encompasses not just how much mass the object has
overall, but how far each bit of mass is from the axis. The further
out the object's mass is, the more rotational inertia the object has,
and the more torque (force × distance from axis of rotation) is
required to change its rotation rate. For example, consider two
hoops, A and B, made of the same material and of equal mass.
Hoop A is larger in diameter but thinner than B. It requires more
effort to accelerate hoop A (change its angular velocity) because
its mass is distributed farther from its axis of rotation: mass that is
farther out from that axis must, for a given angular velocity, move
more quickly than mass closer in. So in this case, hoop A has a
larger moment of inertia than hoop B.
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